Search results
Showing 451 to 465 of 1553 results for do not do recommendations
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.
Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Early years: promoting health and wellbeing in under 5s (QS128)
This quality standard covers services to support the health, and social and emotional wellbeing of children under 5, including vulnerable children who may need extra support. It includes health visitor services, childcare and early years education, and early intervention services in children’s social care. It describes high-quality care in priority areas for improvement.
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
View recommendations for NG182Show all sections
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.
View quality statements for QS135Show all sections
Sections for QS135
- Quality statements
- Quality statement 1: Providing information about potential signs and symptoms of preterm labour
- Quality statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage
- Quality statement 3: Information for women having a planned preterm birth
- Quality statement 4: Tocolysis for women between 26+0 and 33+6 weeks of pregnancy
- Quality statement 5: Corticosteroids for women between 24+0 and 33+6 weeks of pregnancy
- Quality statement 6: Magnesium sulfate for women between 24+0 and 29+6 weeks of pregnancy
- Update information
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities